Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort study

Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: 9d3174126b174217083ad3c9f1b62d5060894c1d
First added on: Feb 19, 2025